Aktis Oncology (AKTS) stock: insider trades, news & valuation
Strong buyingShare price and insider trades
Aktis Oncology insider trading at a glance (Oct 9, 2026): in the past 12 months, 6 insiders bought $114M and 3 sold $3.2M of AKTS stock on the open market, including a cluster buy that began Jan 12, 2026.
Get emailed when insiders cluster-buy stocks like AKTS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
AKTS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $3.2M | 11 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | $114M | 9 | — | 0 |
Valuation, profit and volume
Summary
Over the past 12 months, 6 Aktis Oncology, Inc. insiders reported open-market purchases totaling $114M, while 3 insiders reported sales totaling $3.2M. The most recent cluster buy began on Jan 12, 2026, when 6 insiders bought a combined $114M. 2 of 11 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
AKTS earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 13, 2026 | +4.5% | Sold $197K | +3.9%S&P +0.5% | -6.5% |
| May 11, 2026 | -15.8% | None | +6.1%S&P +0.1% | -1.4% |
| Mar 30, 2026 | -16.9% | None | +17.8%S&P +2.6% | +4.8% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 24SEC | Akos CzibereChief Medical Officer | Sell Plan | 7,401 | $21.03 | $156K | -13.7% | — |
| Sep 24SEC | Akos CzibereChief Medical Officer | Sell Plan | 5,0997,401 held (−41%) | $20.19 | $103K | -10.1% | — |
| Jul 21SEC | Ken HerrmannDirector | Sell | 3,5061,350 held (−72%) | $24.56 | $86K | -26.1% | — |
| Jul 21SEC | Ken HerrmannDirector | Sell | 1,350 | $24.56 | $33K | -26.1% | — |
| Jul 20SEC | Ken HerrmannDirector | Sell | 3,065 | $25.21 | $77K | -28.0% | — |
| Jul 10SEC | Akos CzibereChief Medical Officer | Sell | 30,8294,371 held (−88%) | $27.95 | $862K | -35.1% | — |
| Jul 10SEC | Shulamit Ron-biggerCOO | Sell | 30,0004,200 held (−88%) | $27.94 | $838K | -35.0% | — |
| Jul 10SEC | Shulamit Ron-biggerCOO | Sell | 15,80034,200 held (−32%) | $27.13 | $429K | -33.1% | — |
| Jul 10SEC | Akos CzibereChief Medical Officer | Sell | 14,80035,200 held (−30%) | $27.13 | $402K | -33.1% | — |
| Jul 10SEC | Akos CzibereChief Medical Officer | Sell | 4,371 | $28.71 | $125K | -36.8% | — |
| Jul 10SEC | Shulamit Ron-biggerCOO | Sell | 4,200 | $28.75 | $121K | -36.9% | — |
| Jan 14SEC | Mpm Oncology Innovations Fund Lp10% Owner | Buy | 1,112,77710,260,064 held (+12%) | $18.00 | $20.0M | +0.8% | — |
| Jan 14SEC | Ansbert Gadicke10% Owner | Buy | 1,112,77710,260,064 held (+12%) | $18.00 | $20.0M | +0.8% | — |
| Jan 14SEC | Todd FoleyDirector | Buy | 232,8704,235,403 held (+6%) | $18.00 | $4.2M | +0.8% | — |
| Jan 12SEC | Oleg NodelmanDirector | Buy | 2,077,7794,348,658 held (+91%) | $18.00 | $37.4M | +0.8% | — |
| Jan 12SEC | Vida Ventures Ii-A, Llc10% Owner | Buy | 812,4555,671,825 held (+17%) | $18.00 | $14.6M | +0.8% | — |
| Jan 12SEC | Helen Susan KimDirector | Buy | 812,4555,671,825 held (+17%) | $18.00 | $14.6M | +0.8% | — |
| Jan 12SEC | Oleg NodelmanDirector | Buy | 144,443347,305 held (+71%) | $18.00 | $2.6M | +0.8% | — |
| Jan 12SEC | Vida Ventures Ii-A, Llc10% Owner | Buy | 22,545157,387 held (+17%) | $18.00 | $406K | +0.8% | — |
| Jan 12SEC | Helen Susan KimDirector | Buy | 22,545157,387 held (+17%) | $18.00 | $406K | +0.8% | — |
Insiders at Aktis Oncology, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Oleg NodelmanDirector | $40.0M | — | Jan 12, 2026 | — |
| Mpm Oncology Innovations Fund Lp10% Owner | $20.0M | — | Jan 14, 2026 | — |
| Ansbert Gadicke10% Owner | $20.0M | — | Jan 14, 2026 | — |
| Vida Ventures Ii-A, Llc10% Owner | $15.0M | — | Jan 12, 2026 | — |
| Helen Susan KimDirector | $15.0M | — | Jan 12, 2026 | — |
| Todd FoleyDirector | $4.2M | — | Jan 14, 2026 | — |
| Akos CzibereChief Medical Officer | — | $1.6M | Sep 24, 2026 | — |
| Shulamit Ron-biggerCOO | — | $1.4M | Jul 10, 2026 | — |
| Ken HerrmannDirector | — | $197K | Jul 21, 2026 | — |
AKTS stock: common questions
Are Aktis Oncology, Inc. insiders buying AKTS stock?
In the past 12 months, 6 insiders reported open-market purchases of AKTS worth $114M. The latest was 10% Owner Mpm Oncology Innovations Fund Lp bought $20.0M of AKTS at $18.00 — first open-market purchase in our records.
Are Aktis Oncology, Inc. insiders selling AKTS stock?
3 insiders reported sales worth $3.2M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is AKTS's 52-week range?
Over the past year AKTS has traded between $15.19 and $32.23. It last closed at $18.15 on Oct 9, 2026.